Cargando…
MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)
Monogenic Diabetes (MODY) results from mutations or changes in a single gene, and currently account for about 1 to 4% of all cases of diabetes (1). Our group has previously published on the successful use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in three consecutive generations...
Autores principales: | Broome, David Tyler, Pantalone, Kevin M, Mehta, Adi Erach |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209230/ http://dx.doi.org/10.1210/jendso/bvaa046.397 |
Ejemplares similares
-
MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn, et al.
Publicado: (2019) -
SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023) -
Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY
por: Broome, David T., et al.
Publicado: (2020) -
MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019) -
SUN-129 Early Onset Of MODY 5 Due To The Haploinsufficency HNF1B Gene As Part Of 17q12 Deletion
por: Bustamante Escobar, Carmen, et al.
Publicado: (2019)